ProfessorNick Hopkinson
Professor of Respiratory Medicine
National Heart & Lung Institute - Faculty of Medicine
Orcid identifier0000-0003-3235-0454 (opens in a new tab)
- Professor of Respiratory MedicineNational Heart & Lung Institute - Faculty of Medicine
- Muscle Lab, South Block, Royal Brompton Campus, United Kingdom
RESEARCH
Lung volume reduction in COPD: These approaches offer a chance to improve symptoms dramatically in what is otherwise a progressive disease. Starting with the first case series describing bronchoscopic lung volume reduction with endobronchial valves he showed it to be one of the very few interventions which improves survival in COPD that it reduces dynamic hyperinflation during exercise and improves chest wall synchrony and oxygen kinetics. He led the MRC funded BeLieVeR-HIFi study, the first double blind randomised controlled trial of endobronchial valves and the CELEB trial, a multicentre NIHR funded study comparing valve placement and surgery directly. The UKLVR study is an Asthma Lung UK funded project to develop a national Lung Volume Reduction Register.
Physical activity limitation and Skeletal muscle dysfunction in COPD: This has included demonstrating that skeletal muscle weakness occurs even in early COPD associated with reduced physical activity levels, investigating the effect of ACE-I and oral nitrate supplementation on skeletal muscle in COPD. International collaborations include the EU/IMI PROactive project developing a patient reported outcome for physical activity in COPD and the Horizon 2020 MOBILISE-D project developing digital mobility outcomes.
Smoking and tobacco control: He is Chair of Action on Smoking and Health (ASH) and serves on the Royal College of Physicians Tobacco Advisory Committee. Work to prevent uptake of smoking and help smokers to quit is fundamental to addressing the burden of COPD. Highlighting rates of child uptake of smoking contributed to the adoption of measures on standardised packaging for tobacco products and the ban on smoking in cars with children. Collaborations include the FRESHAIR project promoting lung health in low and middle income countries and work on the global environmental impact of tobacco production and consumption.
High value care: COPD affects 1.3 million people in the UK. Ensuring that they receive good care and that high value interventions are prioritised is a major challenge. Key activities include developing the COPD discharge care bundle focusing on the delivery of high value interventions. This is linked to the pyramid of value concept - emphasising the evidence base and low cost per QALY of interventions in COPD including flu vaccination and pulmonary rehabilitation.
With the London Respiratory Network he developed the Breathing SPACE approach for reviewing the care of any chronically breathless patient.
Physical activity limitation and Skeletal muscle dysfunction in COPD: This has included demonstrating that skeletal muscle weakness occurs even in early COPD associated with reduced physical activity levels, investigating the effect of ACE-I and oral nitrate supplementation on skeletal muscle in COPD. International collaborations include the EU/IMI PROactive project developing a patient reported outcome for physical activity in COPD and the Horizon 2020 MOBILISE-D project developing digital mobility outcomes.
Smoking and tobacco control: He is Chair of Action on Smoking and Health (ASH) and serves on the Royal College of Physicians Tobacco Advisory Committee. Work to prevent uptake of smoking and help smokers to quit is fundamental to addressing the burden of COPD. Highlighting rates of child uptake of smoking contributed to the adoption of measures on standardised packaging for tobacco products and the ban on smoking in cars with children. Collaborations include the FRESHAIR project promoting lung health in low and middle income countries and work on the global environmental impact of tobacco production and consumption.
High value care: COPD affects 1.3 million people in the UK. Ensuring that they receive good care and that high value interventions are prioritised is a major challenge. Key activities include developing the COPD discharge care bundle focusing on the delivery of high value interventions. This is linked to the pyramid of value concept - emphasising the evidence base and low cost per QALY of interventions in COPD including flu vaccination and pulmonary rehabilitation.
With the London Respiratory Network he developed the Breathing SPACE approach for reviewing the care of any chronically breathless patient.
GRANTS
- INTERNAL SCHEMEBRC Respiratory Theme Pilot Projects BudgetImperial College Healthcare NHS Trust- BRC Funding